Literature DB >> 8827083

Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome.

H Suzuki1, K Akakura, A Komiya, S Aida, S Akimoto, J Shimazaki.   

Abstract

The growth of prostate cancer is androgen responsive, and androgen receptor (AR) is thought to play an important role in the development of this cancer. Recently, some reports demonstrated that AR gene mutations were detected in human prostate cancer tissues. We have previously reported that one of eight endocrine therapy-resistant prostate cancer cases showed AR gene mutation [Suzuki et al: J Steroid Biochem Mol Biol 46:759-765, 1993]. To further investigate structural abnormality of the AR in a large number of human prostate cancers, exons B-H encoding DNA-and hormone-binding domains were examined by single-strand conformation polymorphism analysis of polymerase chain reaction products and direct sequencing. Tissues surgically removed from 30 cases of stage B or C prostate cancer and from 22 cases of endocrine therapy-resistant cancers obtained at autopsy were used in the study. Three out of 22 cancer death cases (14%) revealed AR gene mutations, one of which contained two different mutations-exon D in cancerous prostate and exon H in metastatic tissues. In the other two cases, AR gene mutations in exon H were found in metastatic tissues. All three cases in metastatic tissues showed the same mutation at codon 877 (877Thr-->Ala). In stage B or C cancer tissues and the other cancer death samples, no AR mutation was detected. The mutation in exon H was identical to that reported in a human prostate cancer cell line, LNCaP. These results indicate that AR gene mutation scarcely occurs in the early stage of prostate cancer and that the mutation is found in relation to endocrine therapy resistance. Two patients with an AR gene mutation at codon 877 revealed a remarkable fall in prostate-specific antigen after withdrawal of antiandrogen. Data on the other case were not available. These results indicate that a codon 877 mutation in the AR gene in advanced prostate cancer evokes the antiandrogen withdrawal syndrome. To our knowledge, this report is the first description of relationship between an AR mutation at codon 877 and the antiandrogen withdrawal syndrome.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8827083     DOI: 10.1002/1097-0045(199609)29:3<153::aid-pros2990290303>3.0.co;2-5

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  42 in total

Review 1.  Androgens and prostate cancer.

Authors:  Alan I So; Antonio Hurtado-Coll; Martin E Gleave
Journal:  World J Urol       Date:  2003-10-29       Impact factor: 4.226

Review 2.  Chemistry and structural biology of androgen receptor.

Authors:  Wenqing Gao; Casey E Bohl; James T Dalton
Journal:  Chem Rev       Date:  2005-09       Impact factor: 60.622

3.  Antitumor agents. 250. Design and synthesis of new curcumin analogues as potential anti-prostate cancer agents.

Authors:  Li Lin; Qian Shi; Alexander K Nyarko; Kenneth F Bastow; Chin-Chung Wu; Ching-Yuan Su; Charles C-Y Shih; Kuo-Hsiung Lee
Journal:  J Med Chem       Date:  2006-06-29       Impact factor: 7.446

4.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone.

Authors:  J S Sack; K F Kish; C Wang; R M Attar; S E Kiefer; Y An; G Y Wu; J E Scheffler; M E Salvati; S R Krystek; R Weinmann; H M Einspahr
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-24       Impact factor: 11.205

Review 5.  The convergence of hormone regulation and cell cycle in prostate physiology and prostate tumorigenesis.

Authors:  Joanne N Davis; Mark L Day
Journal:  Mol Biotechnol       Date:  2002-10       Impact factor: 2.695

6.  3 beta-acetoxyandrost-1,5-diene-17-ethylene ketal functions as a potent antiandrogen with marginal agonist activity.

Authors:  Hiroshi Miyamoto; Padma Marwah; Ashok Marwah; Henry Lardy; Chawnshang Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2003-04-02       Impact factor: 11.205

7.  Suppression of Delta(5)-androstenediol-induced androgen receptor transactivation by selective steroids in human prostate cancer cells.

Authors:  H C Chang; H Miyamoto; P Marwah; H Lardy; S Yeh; K E Huang; C Chang
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-28       Impact factor: 11.205

8.  Rational design of novel antiandrogens for neutralizing androgen receptor function in hormone refractory prostate cancer.

Authors:  Pratap Singh; Gurulingappa Hallur; Ravi K Anchoori; Oladapo Bakare; Yukio Kageyama; Saeed R Khan; John T Isaacs
Journal:  Prostate       Date:  2008-10-01       Impact factor: 4.104

9.  Androgen receptor and immune inflammation in benign prostatic hyperplasia and prostate cancer.

Authors:  Kouji Izumi; Lei Li; Chawnshang Chang
Journal:  Clin Investig (Lond)       Date:  2014-10-01

10.  A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.

Authors:  Yiu-Keung Lau; Manpreet K Chadha; Alan Litwin; Donald L Trump
Journal:  J Hematol Oncol       Date:  2008-11-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.